Interdisciplinary Collaboration to Develop a Custom Genomic Analysis Pipeline for the Clinical Laboratory: Hepatitis B Virus and Cytomegalovirus Antiviral Resistance Genotyping
Clinical Chemistry · 2025
DOI: 10.1093/clinchem/hvaf093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Gordon Ritchie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Hepatitis B virus, Drug Resistance, Viral, Cytomegalovirus, Antiviral Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Next-generation sequencing for hepatitis B virus (HBV) and cytomegalovirus (CMV) antiviral drug resistance (AVDR) testing improves the sensitivity of variant detection, but availability of bioinformatics and analytical pipelines are key barriers to implementation.
Methods
Plasma was extracted on MagNA Pure 24 (Roche Diagnostics) and next-generation sequencing performed on GridION (Oxford Nanopore Technologies) with R.10.4.1 flowcells. An in-house bioinformatics pipeline was developed using Nextflow and deployed on Microsoft Azure to process FASTQ files and automate reporting of HBV genotype and AVDR, as well as CMV AVDR (UL97/54).
Results
A total of 71 samples for HBV genotyping and AVDR testing and 56 samples for CMV AVDR testing were analyzed and compared to reference pipelines (DeepChek® HBV and CMV). All HBV genotypes and resistant mutations were concordant. For CMV, 74 mutations were identified in the UL97/54 region by both pipelines. However, our in-house developed method identified an additional UL97 drug resistant mutation (del598-603) in one sample.
Conclusions
A custom bioinformatics pipeline was developed for HBV and CMV genotyping and AVDR sequencing, which could be adapted to other targets to enable our clinical laboratory to expand clinical testing using next-generation sequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
- Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Vancouver, BC, Canada.
- Daric Clouding Solutions, Vancouver, BC, Canada.
- Microsoft Genomics Team, Redmond, WA, United States.
- Microsoft Health and Life Sciences, Toronto, ON, Canada.
ORCID-Profile: Michael Payne, Aleksandra Stefanovic, Nancy Matic, Christopher F Lowe
Zitieren
APA
Ritchie, G., Mobini, M., Malladi, V. S., Lawson, T., Young, M., Jang, W., Mohammadi, H., Payne, M., Stefanovic, A., Tang, P., Romney, M. G., Holmes, D. T., Matic, N., & Lowe, C. F. (2025). Interdisciplinary Collaboration to Develop a Custom Genomic Analysis Pipeline for the Clinical Laboratory: Hepatitis B Virus and Cytomegalovirus Antiviral Resistance Genotyping. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaf093
Vancouver
Ritchie G, Mobini M, Malladi VS, Lawson T, Young M, Jang W, et al. Interdisciplinary Collaboration to Develop a Custom Genomic Analysis Pipeline for the Clinical Laboratory: Hepatitis B Virus and Cytomegalovirus Antiviral Resistance Genotyping. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvaf093
BibTeX
@article{Ritchie2025,
author = {Ritchie, Gordon and Mobini, Mahdi and Malladi, Venkat S and Lawson, Tanya and Young, Matthew and Jang, Willson and Mohammadi, Helia and Payne, Michael and Stefanovic, Aleksandra and Tang, Patrick and Romney, Marc G and Holmes, Daniel T and Matic, Nancy and Lowe, Christopher F},
title = {Interdisciplinary Collaboration to Develop a Custom Genomic Analysis Pipeline for the Clinical Laboratory: Hepatitis B Virus and Cytomegalovirus Antiviral Resistance Genotyping},
journal = {Clinical Chemistry},
year = {2025},
doi = {10.1093/clinchem/hvaf093}
}
EUVIMED